Disease Modification in Multiple Sclerosis by Flupirtine—Results of a Randomized Placebo Controlled Phase II Trial

Central nervous system inflammation and neurodegeneration are the pathophysiological hallmarks of multiple sclerosis (MS). While inflammation can readily be targeted by current disease modifying drugs, neurodegeneration is by far less accessible to treatment. Based on suggested additional neuroprote...

Full description

Saved in:
Bibliographic Details
Published in:Front Neurol
Main Authors: Dörr, Jan, Wernecke, Klaus-Dieter, Würfel, Jens, Bellmann-Strobl, Judith, Siffrin, Volker, Sättler, Muriel B., Simons, Mikael, Linsa, Andreas, Tumani, Hayrettin, Paul, Friedemann
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2018
Subjects:
Neurology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6190842/
https://ncbi.nlm.nih.gov/pubmed/30356868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2018.00842
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items